PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 151 filers reported holding PROGENICS PHARMACEUTICALS IN in Q1 2019. The put-call ratio across all filers is 1.60 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $77,000 | -73.7% | 20,289 | -64.8% | 0.00% | -75.0% |
| Q4 2019 | $293,000 | -42.9% | 57,629 | -43.2% | 0.00% | -33.3% |
| Q3 2019 | $513,000 | -36.7% | 101,500 | -22.8% | 0.01% | -33.3% |
| Q2 2019 | $811,000 | +34.0% | 131,454 | +0.8% | 0.01% | +28.6% |
| Q1 2019 | $605,000 | +10.6% | 130,419 | +0.2% | 0.01% | 0.0% |
| Q4 2018 | $547,000 | -28.3% | 130,195 | +7.0% | 0.01% | 0.0% |
| Q3 2018 | $763,000 | -11.5% | 121,636 | +13.4% | 0.01% | -22.2% |
| Q2 2018 | $862,000 | +4.2% | 107,274 | -3.3% | 0.01% | +12.5% |
| Q1 2018 | $827,000 | +17.6% | 110,905 | -6.1% | 0.01% | +14.3% |
| Q4 2017 | $703,000 | +161.3% | 118,105 | +223.6% | 0.01% | +133.3% |
| Q3 2017 | $269,000 | +8.0% | 36,500 | -0.3% | 0.00% | 0.0% |
| Q2 2017 | $249,000 | -27.8% | 36,600 | +0.3% | 0.00% | -40.0% |
| Q1 2017 | $345,000 | – | 36,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 8,951,169 | $54,871,000 | 3.38% |
| Virtus ETF Advisers LLC | 103,807 | $636,000 | 1.75% |
| BKS ADVISORS, LLC | 291,150 | $1,785,000 | 0.92% |
| Piermont Capital Management Inc. | 363,549 | $2,229,000 | 0.71% |
| TUDOR INVESTMENT CORP ET AL | 2,370,760 | $14,532,000 | 0.41% |
| SEARLE & CO. | 60,000 | $349,000 | 0.34% |
| TURNER INVESTMENTS LLC | 252,785 | $1,550,000 | 0.32% |
| RICE HALL JAMES & ASSOCIATES, LLC | 891,672 | $5,466,000 | 0.31% |
| Phocas Financial Corp. | 635,333 | $3,895,000 | 0.30% |
| TFS CAPITAL LLC | 398,283 | $2,441,000 | 0.26% |